Skip to Main Content
CWRU Links
Case Comprehensive Cancer Center

Case CCC Funding Opportunities

Case CCC Funding Opportunities

Opportunities for Pilot Projects in Genomics

DEADLINE: Friday, April 21, 2017

The Case Comprehensive Cancer Center is providing seed funding for the initiation of novel projects that focus on genomic analyses of tissue/blood samples from patients seen at University Hospitals of Cleveland. Projects must be aligned with at least one of the seven Research Programs (GI Cancer Genetics, Molecular Oncology, GU Malignancies, Hematopoietic and Immune Cancer Biology, Developmental Therapeutics, Cancer Imaging, or Cancer Prevention, Control, & Population Research) or the Brain Tumor, Breast Cancer, or AYA research initiatives within the Center. Highly innovative and impactful proposals are sought that will generate key data for larger, nationally competitive grants that interface with the Strategic Plan of the aligned program(s). Collaborative, multi-investigator projects are particularly encouraged. Analysis of samples obtained from patients in clinical trials, high risk families, or underserved populations are particularly encouraged. Use of genomics tools is required with preference for sequencing and analytics studies preferred through the genomics shared resource or through UHTL. IRB review may be pending at the time of submission.

Award Description:

  • Funding for research teams with projects that are aligned with one of the Cancer Center Research Programs or Initiatives.
  • Up to 5 research projects will be funded. Total funds committed to this RFA are $250,000.
  • Each research project can request a budget of up to $50,000 for one year.
  • Research projects should be completed within 1 year.

Funding Criteria:

  • Strong collaborative investigative teams of Case Comprehensive Cancer Center members that clearly demonstrate programmatic alignment.
  • PI must be at the rank of Assistant Professor or higher at CWRU at the time of submission.
  • Highly innovative and impactful projects.
  • All materials to complete the project should be in-hand or readily available. At the time of award, an approved IRB protocol for patient cohort collection will be needed. Collection of new patient cohorts is responsive to this RFA with IRB approval.
  • Projects must have a high likelihood of subsequent national-level funding.
  • While investigators can be collaborators on multiple applications, only one application will be accepted per lead PI.
  • It is preferred that funds for core facilities use Case Comprehensive Cancer Center cores, when available.

View detailed instructions: [genomics-instructions-2017]

Contact casecccpilots@case.edu or Megan Kilbane at 216.286.4440 with any questions.

Opportunities for Pilot Projects in Cancer Disparities Research

DEADLINE: Friday, April 7, 2017

A major goal of the Office of Cancer Disparities Research and the Case Comprehensive Cancer Center (Case CCC) at Case Western Reserve University is to reduce and eliminate social and racial/ethnic disparities in cancer outcomes. Efforts toward overcoming cancer disparities have great potential to achieve cancer health equity. However, research advances in cancer prevention, detection, screening, diagnosis, treatment, and survivorship have not affected all segments of the U.S. population equally, particularly those characterized by race/ethnicity, socioeconomic status, health insurance status, and/or geographic location. Many of these disparities are also observed within the Case CCC catchment area. The main goal of this RFA is to stimulate novel research designed to (1) improve understanding of the causes of cancer disparities and (2) develop and test interventions for reducing and ultimately eliminating them. Transdisciplinary, interprogrammatic, and translational approaches are especially encouraged, as are new investigator proposals.

This announcement seeks projects that (1) explicitly apply concepts and models from the behavioral and social sciences to health care, behavior change, disease prevention, and public policy, or (2) investigate biological/genetic bases of cancer disparities, such as mechanistic studies of biological pathways that lead to downstream disparities, or the development and testing of new methodologies and models. Basic science proposals must clearly demonstrate the relevance to cancer outcome disparities. We encourage applications in clinical oncology research, basic molecular mechanistic approaches, population genetics, epidemiology, health psychology, bio-behavioral oncology, community-based participatory research (CBPR), and structural biologic approaches to cancer therapy.

Areas of inquiry can include (but are not limited to)

  • Understanding the Causes and Mechanisms of Cancer: Basic, clinical, and population research to improve understanding of the genetic, epigenetic, environmental, behavioral, and sociocultural determinants of cancer and the biological mechanisms underlying cancer resistance, susceptibility, initiation, regression, progression, and recurrence.
  • Accelerating Progress in Cancer Prevention: Accelerate the discovery, development, and delivery of cancer prevention interventions by investing in research focused on risk assessment, systems biology, behavior modifications, environmental and policy influences, and medical and nutritional approaches.
  • Improving Early Detection and Diagnosis: The development and dissemination of interventions to detect and diagnose early-stage malignancy.
  • Developing Effective and Efficient Treatments: The development and dissemination of interventions to treat malignancy by either destroying all cancer cells or modulating and controlling metastasis, both with minimal harm to healthy tissue.
  • Understanding Factors that Influence Cancer Outcomes: Studies to increase our understanding of and ability to measure the environmental, behavioral, sociocultural, and economic influences that affect the quality of cancer care, survivorship, and health disparities.
  • Improving the Quality of Cancer Care: The development and dissemination of quality improvement interventions and measure their success in improving healthrelated outcomes across the cancer continuum.
  • Improving the Quality of Life for Cancer Patients, Survivors, and Their Families: The development and dissemination of interventions to reduce the adverse effects of cancer diagnosis and treatment and improve health-related outcomes for cancer patients, survivors, and their families.

Funding Criteria:

  • Up to 3 pilots of $50,000 will be awarded.
  • Strong collaborative investigative teams of Case Comprehensive Cancer Center members that clearly demonstrate programmatic alignment.
  • Highly innovative and impactful projects.
  • All materials to complete the project should be in-hand or readily available. For example, tissue-based research will require an approved IRB protocol and patient cohort studies must have already recruited the cohort. Collection of new patient cohorts is not responsive to this RFA.
  • Projects must have a high likelihood of subsequent national-level funding.
  • While investigators can be collaborators on multiple applications, only one application will be accepted per lead PI.
  • All funds for core facilities must use Case Comprehensive Cancer Center cores, when available, rather than cores at institutions outside Cleveland.

View detailed instructions: [cancer-disparities-instructions-2017]

Contact casecccpilots@case.edu or Megan Kilbane at 216.286.4440 with any questions.

Request for Proposals for Case CCC Funding for Pilot/Phase I Clinical Trials

The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions.

The proposals are being accepted on a rolling basis subject to availability of funds.

Please direct any questions and/or submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office, katarzyna.karelus@case.edu, 216.844.4176.